Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Di'ao Xinxuekang for prevention of anthracycline-associated cardiotoxicity in breast cancer
ChiCTR2300072819Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Anthracycline Cardiomyopathy comparing Xinxuekang Group with Placebo Group (2 arms). Primary endpoint: Proportion of patients with high-sensitivity troponin T increased twofold from baseline. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
di'ao xinxuekang
03
Conditions
Anthracycline Cardiomyopathy
Beyond the preview
Go deeper on ChiCTR2300072819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072819.